OpenEvidence supply constrained high CPM ads

Selling ads against only 5% of inventory means OpenEvidence is supply constrained, not demand constrained. The business is making most of its money from a tiny slice of clinician sessions, which implies it could grow revenue a lot without adding many more doctors, simply by showing ads in more searches, more screens, or more adjacent workflows like note taking and patient calling. That is why a free product can scale toward software like revenue at ad like margins.1 2 3

• The math points to unusually valuable ad slots. OpenEvidence was already getting $70 to $150+ CPM in late 2025 by placing pharma and med device ads inside physician research workflows, then later pushed into four figure CPM territory while still monetizing only 5% of inventory. That suggests advertisers are paying for access to rare, high intent clinical moments, not broad reach.2 1
• This looks more like rationing premium inventory than filling every page with ads. Doctors use OpenEvidence during diagnosis and treatment research, where a single impression can influence drug choice, device selection, or follow up testing. Keeping ad load low protects the product from feeling like a trade publication and helps preserve the trust and daily habit driving 65%+ monthly and 50%+ daily use among U.S. physicians.1 2 3
• The closest public analog is Doximity, which also turns physician attention into advertising revenue, but OpenEvidence sits deeper in the clinical workflow. Doximity monetizes the physician network and communication layer, while OpenEvidence monetizes the research moment itself, where buyer intent is tighter and CPMs can support much higher revenue per impression even with very limited ad density.2 4

The next step is straightforward. OpenEvidence can widen monetization from search into scribes, coding, calling, prescribing, and enterprise surfaces, while still keeping ads scarce enough to feel premium. If it does that, the company moves from a fast growing doctor search tool into the default physician interface, with advertising as the first revenue stream and workflow ownership as the larger prize.1 2